Key Highlights

• Mesoblast (ASX:MSB) closed at A$2.17, rising 3.33% on 05 November 2026, as the ASX 200 Health Care index gained 3.64%

• Ryoncil net Revenue reached US$28 million in Q1, up 44% on the prior corresponding period, with September recording the highest monthly new patient starts

• All patients were treated in the Phase 3 pivotal trial of rexlemestrocel-L for chronic inflammatory low back pain, with 12-month readout expected next year

Shares of Mesoblast Ltd (ASX:MSB) closed at A$2.17 on 05 November 2026, gaining 3.33% during the session. The broader S&P/ASX 200 (XJO) advanced 2.61%, adding 230.60 points to close at 9,065.10, while the S&P/ASX 200 Health Care index (XHJ) gained 3.64%, rising 1,240.30 points to 35,329.10. The positive session was supported by overnight Wall Street gains following the Democrats' decisive victory in the U.S. midterm elections. Mesoblast is a global leader in allogeneic cellular medicines for inflammatory diseases, listed on both the ASX and Nasdaq (MESO).

Ryoncil Revenue Continues to Grow

In its Q1 FY2027 activity report released on 28-29 October 2026, Mesoblast disclosed that Ryoncil (remestemcel-L-rknd) net revenue for the first quarter was US$28 million, representing a 44% increase compared with the prior year period. September experienced the highest number of new patient starts per month, following expected seasonal patterns where summer recess typically affects treatment scheduling in July and August. The registration trial for expansion of Ryoncil use for adults with steroid-refractory acute graft versus host disease (SR-aGvHD) has commenced enrolment, with up to 40 sites across the U.S. expected to be activated, representing approximately 60% of the estimated 8,500 annual U.S. allogeneic adult bone marrow transplant population.

Phase 3 Back Pain Trial Completed

Mesoblast completed treatment of all enrolled patients in its expanded 350-patient Phase 3 pivotal trial of rexlemestrocel-L for chronic inflammatory low back pain due to degenerative disc disease. The trial's primary endpoint of 12-month durable pain reduction is expected to read out next year. The company noted Demand from trial investigators to enroll their patients was high throughout the study.

FDA Meeting on Heart Failure BLA Filing

Mesoblast met with the FDA to align on the Biologics License Application filing for rexlemestrocel-L under its Regenerative Medicine Advanced Therapy (RMAT) and Orphan Drug designations. The product is targeted at treatment of patients with end-stage heart failure with reduced ejection fraction (HFrEF) being kept alive by a left ventricular assist device. The FDA confirmed the BLA filing may proceed for patients with life-threatening major gastrointestinal bleeding, a complication of vascular inflammation and abnormalities in these patients. Formal minutes of the meeting were expected shortly at the time of reporting.

Financial Position

Mesoblast held US$99 million of cash at 30 September 2026. The company reported US$2.1 million in operating cash spend for the first fiscal quarter, representing an 86% improvement compared with US$14.9 million in the prior year period. The reduction in cash burn was achieved while the company continued to advance its clinical and commercial objectives.

About Mesoblast – Business Overview

Mesoblast is headquartered in Melbourne with operations in New York and Singapore. The company develops allogeneic, off-the-shelf cellular medicines that target inflammatory conditions by releasing anti-inflammatory factors to modulate the immune system. Ryoncil is the first FDA-approved mesenchymal stromal cell therapy, currently indicated for paediatric SR-aGvHD. The company's pipeline also includes rexlemestrocel-L for chronic low back pain and heart failure applications. Mesoblast holds over 1,000 granted patents or applications globally, with commercial protection extending through at least 2044.

Sector Context

The healthcare sector recorded a positive session with the XHJ index gaining 3.64%. Biotech stocks participated in the broader rally, with Mesoblast's 3.33% gain tracking close to the sector benchmark. The risk-on environment driven by the U.S. midterm election outcome supported buying interest across the healthcare sector.

Risks

Key risks include the outcome of the Phase 3 back pain trial readout, regulatory decisions on the heart failure BLA filing, and Ryoncil's commercial trajectory in the competitive GvHD treatment landscape. Manufacturing scale-up challenges as Mesoblast expands production for potential adult indications represent operational risks. The company's reliance on a single approved product for revenue, combined with ongoing clinical trial expenses, means the sustainability of improved cash metrics will depend on continued revenue growth.

Catalysts on Watch

The 12-month readout from the Phase 3 back pain trial is a significant upcoming catalyst. Progress on the FDA BLA filing for rexlemestrocel-L in heart failure, the expansion of the adult SR-aGvHD registration trial, and Ryoncil revenue trends will be closely monitored. FDA formal meeting minutes and any manufacturing milestones could also be material.

The Bottom Line

Mesoblast's Q1 FY2027 results highlighted a growing commercial business through Ryoncil, with revenue up 44% and cash burn reduced by 86%. The completion of patient treatment in the Phase 3 back pain trial and a constructive FDA meeting on the heart failure BLA filing position the company for multiple potential catalysts over the coming year, supported by a US$99 million cash position.